Immunotherapy for Cancers | Anonamed x TheOncologists.com

How to read the network

Current status by cancer type

Strong current-use or major standard-care role

Bladder Cancer, Blood Cancer, Breast Cancer, Esophageal Cancer, Kidney Cancer, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Stomach Cancer

Selected use, subtype-specific use, or biomarker-driven use

Colon Cancer, Oral Cancer, Ovarian Cancer, Prostate Cancer, Rectal Cancer, Skin Cancer, Throat / Head and Neck Cancer, Thyroid Cancer

Mainly clinical-trial or frontier research focus

Bone Cancer, Brain Cancer, Glioma, Pancreatic Cancer, Testicular Cancer

Start here

Immunotherapy for Cancers: questions to ask before it is too late

Not medical advice

This guide helps patients and families prepare questions. It does not diagnose cancer, recommend treatment, replace your oncology team, or tell anyone to start, stop, delay, or refuse treatment.

Not right for everyone

Immunotherapy can help some patients greatly and does not help others. Not being offered immunotherapy can be medically appropriate because of cancer type, stage, biomarkers, prior therapy, autoimmune disease, organ transplant, performance status, infection risk, or other health factors.

Side effects can be serious

Immune-related inflammation can affect the lungs, bowel, liver, endocrine glands, skin, kidneys, heart, nervous system, or other organs. Ask which symptoms need same-day advice or emergency care.

The better question: "Is immunotherapy appropriate for my exact cancer type, stage, biomarkers, and current health - and if so, should it be used now?" Start with: "Could biomarker testing change the first treatment choice?"

Diagnosis and staging

What is my exact diagnosis, stage, treatment goal, and urgency? Is there enough tissue for biomarker testing?

Biomarkers and sequence

Which biomarkers are ordered, when will results be back, and could any result change the first treatment choice or trial options?

Access and cost

Who handles prior authorization, copay support, manufacturer assistance, public funding rules, transport, lodging, and financial navigation?

Biomarker testing

Testing can change the first treatment choice

Tissue and blood testing

Ask whether tissue testing, blood-based testing, or both are appropriate. Sometimes a repeat biopsy is considered if the original sample is too small or old.

MSI/MMR and TMB

MSI-H, dMMR, and tumor mutational burden can make immunotherapy more relevant in some cancers, including some tissue-agnostic approvals.

Driver mutations

In some cancers, especially lung cancer, EGFR, ALK, ROS1, BRAF, RET, MET, NTRK, HER2, KRAS, and related results can affect treatment sequence.

Special caution in lung cancer.

In advanced non-small cell lung cancer, molecular results can be critical before first-line therapy when possible. Some driver mutations point to targeted therapy first, and starting immunotherapy before complete molecular results can lead to the wrong sequence or avoidable toxicity.

Patient language access

Cancer Immunotherapy first, then the full hub.

Cancer Immunotherapy

Choose a language to open this cancer immunotherapy hub through Google Translate. Automated translation is for orientation only; clinical decisions still need an oncologist, interpreter, and local treatment advice.

Translate this cancer immunotherapy hub

Cancer-specific sites

Choose a cancer type

Immunotherapy Access & Cost

Questions to ask before it is too late

Ask early

The practical question is not "should I get immunotherapy?" It is: "Is immunotherapy appropriate for my exact cancer type, stage, biomarkers and current health - and if so, should it be used now?"

Test early

Biomarker results such as PD-L1, MSI/MMR, TMB, NGS and disease-specific driver mutations can change the first treatment choice. In lung cancer especially, molecular results can affect whether immunotherapy should wait.

Plan access early

U.S. checkpoint-inhibitor courses can involve six-figure gross drug spending, while CAR-T and cellular therapies can be several hundred thousand dollars before surrounding care. That is not the patient's bill and not a promise that treatment is suitable.

Drug price is not the same as the patient's bill. In the U.S., branded checkpoint inhibitors can involve roughly $100,000-$250,000 in gross drug spending for a treated patient depending on therapy, duration, discounts and stopping early. CAR-T and cellular therapies can list in the several-hundred-thousand-dollar range before surrounding care. Actual out-of-pocket cost depends on insurance, public funding, hospital contracts, assistance programs, country and clinical choices.

Why people miss the window

Delays can come from biopsy, pathology, biomarker testing, referral, prior authorization, local access barriers, transport, cost, comorbidities, infections, rapid decline, or poor performance status.

What families can ask

When will biomarker results be back? Is treatment safe to wait for results? Should a major cancer center or tumor board review this? Are trials relevant before starting treatment?

How access may improve

Competition, patent expiry, biosimilars, negotiated prices, public funding decisions, trial access, and patient awareness can affect access over time. None guarantee lower personal cost.

Next steps

Reliable places to ask for help

CancerCare financial assistance PAN Foundation HealthWell Foundation Leukemia & Lymphoma Society American Cancer Society support NeedyMeds

Privacy: This static guide does not ask for names, diagnosis dates, medical record numbers, insurance IDs, or other personal health information. Use it to prepare questions for your oncology team, hospital financial navigator, insurer, pharmacist, interpreter, or local cancer support service.

Trials and evidence

Reference starting points

NCI: Immunotherapy NCI: CAR T cells ClinicalTrials.gov PubMed reviews

Cost and coverage

Approval is not the same as funding

Immunotherapy access changes frequently. A drug can be approved but not publicly funded, funded only for a precise biomarker or stage, or covered only after standard treatments. Patients should confirm the latest local rules with the treating oncologist, cancer center pharmacist, insurer, public formulary, or hospital financial navigator. This site is educational and does not collect personal health information.

Sources and caution